Page 8 - Dr Reddys

Pricing trend, launches, stability of growth boosters for Dr Reddy's

Near-term outlook and valuation are expected to support the stock price

Sensex falls 884 pts from day's high, ends 77 pts down; Nifty holds 17,100

For the week, the Sensex and the Nifty indices are down 3% each

Dr Reddy's may underperform over concerns about launch of complex products

For rerating, it needs sustained growth in India, recovery in US

Dr Reddy's launches drug in US to treat high blood pressure, heart failure

The tablet is the generic therapeutic equivalent of Diovan, approved by the US Food and Drug Administration

Dr. Reddy's inks pact with Singapore firm to sell Trastuzumab biosimilar

Prestige BioPharma Ltd announced that the two companies have entered into a binding agreement for an exclusive partnership for the supply and commercialisation of Trastuzumab biosimilar

Osho Krishan expects bullish bias in Balrampur Chini, Dr.Reddy's, Whirlpool

According to the technical analyst from Anand Rathi, most technical indicators are in favour of the bullish bias for these three stocks

Mandaviya holds meeting with Dr Reddy's Chairman on Sputnik V supply

Dr Reddy's is in a pact with RDIF to sell 250 million vials of Sputnik V in India.

Back to old normal: Pharma industry returns to pre-pandemic growth level

In this first instalment of a four-part series on how some of the defining numbers in key sectors are springing back to the pre-pandemic level, Sohini Das looks at India's pharmaceutical sector

Dr Reddy's extends fall on disappointing Q1; stock down 14% in 2 days

The stock of the pharmaceutical company was trading at its lowest level since April 9, 2021

Five Indian drugmakers to jointly start trial of Merck & Co's Covid-19 drug

(Reuters) - Five Indian generic drugmakers, including Cipla and Dr Reddy's Laboratories, said on Tuesday they would jointly conduct a clinical trial of Merck & Co's anti-viral drug to treat mild COVID-19 in non-hospitalised patients in India.

Dr Reddy's Laboratories announces commercial launch of Covid-19 drug 2-DG

: Dr. Reddy's Laboratories Ltd on Monday announced the commercial launch of 2-deoxy-D-glucose (2-DG). According to a press release issued by the city-based drug maker, Dr. Reddy's will supply the drug to major government as well as private hospitals across India. In the initial weeks, the company will make the drug available in hospitals across metros and Tier 1 cities, and subsequently expand coverage to the rest of the country. 2-DG manufactured by Dr. Reddy's has a purity of 99.5 per cent and is being sold commercially under the brand name 2DG. The maximum retail price (MRP) of each sachet has been fixed at Rs 990, with a subsidized rate offered to Government institutions, it said. 2-DG, a oral drug was developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a laboratory of the Defence Research and Development Organisation (DRDO), in collaboration with Dr. Reddy's. Dr. G Satheesh Reddy, Secretary, Department of Defence (R&D) and Chairman, DRDO

Nomura remains overweight on India; Infosys, RIL, ICICI Bank among top bets

Going ahead, Nomura said, markets will focus more on corporate earnings rather than the broad economic growth in India

We have sole selling rights, beware of fake agents of Sputnik-V: Dr Reddy's

Hyderabad-based pharma major says it isn't supplying Russia jab to residential societies

DRDO's 2DG anti-Covid drug priced at Rs 990 per sachet: Dr Reddy's

The drug will be provided to government hospitals at a discounted price, ANI quoted government officials as saying.

Dr Reddy's in talks with RDIF to sell Sputnik V in other countries

Dr Reddys Laboratories is in a pact with Russian Direct Investment Fund to sell 250 million vials of Covid-19 vaccine Sputnik V in India

Stocks to watch: L&T, DRL, UPL, Eicher Motors, Happiest Minds, Tata Power

Royal Enfield said it has decided to shut down its two manufacturing facilities between May 13-16 amid a second Covid wave

Lilly signs 3 pacts to expand availability of baricitinib for Covid patient

Eli Lilly has issued additional royalty-free, non-exclusive voluntary licenses to Dr Reddy's Ltd, MSN Laboratories and Torrent Pharmaceuticals

Sun Pharma, Dr Reddy's, Aurobindo recall products in the US market

Sun Pharma, Dr Reddy's Laboratories, Aurobindo Pharma and Jubilant Pharma are recalling products in the US market, the world's largest market for pharmaceutical products, for various reasons

Bull Spread strategy on Dr Reddy's Labs by Nandish Shah of HDFC Securities

The stock price has broken out on the daily chart where it closed above 200-day EMA with higher volumes

Stocks to watch: Nureca, Max Fin, Axis Bank, DRL, Dredging Corp, Affle

Wipro announced the appointment of Rene Mulder as Country Head and Managing Director of its Switzerland operations